Shelia M Violette
Overview
Explore the profile of Shelia M Violette including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
48
Citations
2507
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Liu F, Ryan S, Fahnoe K, Morgan J, Cheung A, Storek M, et al.
Mol Ther
. 2024 Feb;
32(4):1061-1079.
PMID: 38382529
Complement-mediated diseases can be treated using systemic inhibitors. However, complement components are abundant in circulation, affecting systemic inhibitors' exposure and efficacy. Furthermore, because of complement's essential role in immunity, systemic...
2.
Raghu G, Mouded M, Prasse A, Stebbins C, Zhao G, Song G, et al.
Am J Respir Crit Care Med
. 2022 Jul;
206(9):1166-1168.
PMID: 35830489
No abstract available.
3.
Fahnoe K, Liu F, Morgan J, Ryan S, Storek M, Stark E, et al.
Front Immunol
. 2022 Jul;
13:869725.
PMID: 35784298
Sustained complement activation is an underlying pathologic driver in many inflammatory and autoimmune diseases. Currently approved anti-complement therapies are directed at the systemic blockade of complement. Consequently, these therapies provide...
4.
Raghu G, Mouded M, Chambers D, Martinez F, Richeldi L, Lancaster L, et al.
Am J Respir Crit Care Med
. 2022 Jun;
206(9):1128-1139.
PMID: 35771569
Treatment options for idiopathic pulmonary fibrosis (IPF) are limited. To evaluate the efficacy and safety of BG00011, an anti-αβ IgG1 monoclonal antibody, in the treatment of patients with IPF. In...
5.
Krishn S, Salem I, Quaglia F, Naranjo N, Agarwal E, Liu Q, et al.
J Extracell Vesicles
. 2020 Jun;
9(1):1763594.
PMID: 32595914
Prostate cancer (PrCa) cells crosstalk with the tumour microenvironment by releasing small extracellular vesicles (sEVs). sEVs, as well as large extracellular vesicles (LEVs), isolated via iodixanol density gradients from PrCa...
6.
Olsson P, Gustafsson R, Salnikov A, Gothe M, Zeller K, Friman T, et al.
Cell Commun Signal
. 2018 Jul;
16(1):36.
PMID: 29966518
Background: Chemotherapeutic efficacy can be improved by targeting the structure and function of the extracellular matrix (ECM) in the carcinomal stroma. This can be accomplished by e.g. inhibiting TGF-β1 and...
7.
Shea B, Probst C, Brazee P, Rotile N, Blasi F, Weinreb P, et al.
JCI Insight
. 2017 May;
2(9).
PMID: 28469072
Fibrotic lung disease, most notably idiopathic pulmonary fibrosis (IPF), is thought to result from aberrant wound-healing responses to repetitive lung injury. Increased vascular permeability is a cardinal response to tissue...
8.
Desogere P, Tapias L, Hariri L, Rotile N, Rietz T, Probst C, et al.
Sci Transl Med
. 2017 Apr;
9(384).
PMID: 28381537
Pulmonary fibrosis is scarring of the lungs that can arise from radiation injury, drug toxicity, environmental or genetic causes, and for unknown reasons [idiopathic pulmonary fibrosis (IPF)]. Overexpression of collagen...
9.
Gopal S, Veracini L, Grall D, Butori C, Schaub S, Audebert S, et al.
Nat Commun
. 2017 Jan;
8:14105.
PMID: 28102238
Functional interplay between tumour cells and their neoplastic extracellular matrix plays a decisive role in malignant progression of carcinomas. Here we provide a comprehensive data set of the human HNSCC-associated...
10.
McCurley A, Alimperti S, Campos-Bilderback S, Sandoval R, Calvino J, Reynolds T, et al.
J Am Soc Nephrol
. 2017 Jan;
28(6):1741-1752.
PMID: 28062569
Ischemia-reperfusion injury (IRI) is a leading cause of AKI. This common clinical complication lacks effective therapies and can lead to the development of CKD. The v5 integrin may have an...